These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 35296557)

  • 41. Androgen Deprivation Freezes Hormone-Sensitive Prostate Cancer Cells in a Reversible, Genetically Unstable Quasi-Apoptotic State, Bursting into Full Apoptosis upon Poly(ADP-ribose) Polymerase Inhibition.
    Pelliccia A; Capradossi F; Corsi F; Tarquini GD; Bruni E; Reichle A; Torino F; Ghibelli L
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768364
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MicroRNA Regulation of Androgen Receptor in Castration-Resistant Prostate Cancer: Premises, Promises, and Potentials.
    Ebrahimi S; Hashemy SI; Sahebkar A; Aghaee Bakhtiari SH
    Curr Mol Pharmacol; 2021 Oct; 14(4):559-569. PubMed ID: 33357209
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Prognostic value of testosterone during androgene deprivation therapy].
    Vallat A; Pillot P; Lebâcle C; Irani J
    Prog Urol; 2019 Sep; 29(10):510-523. PubMed ID: 31311715
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Maintenance versus discontinuation of androgen deprivation therapy during continuous or intermittent docetaxel administration in castration-resistant prostate cancer patients: A multicentre, randomised Phase III study by the Piemonte Oncology Network.
    Bianchi S; Mosca A; Dalla Volta A; Prati V; Ortega C; Buttigliero C; Fea E; Vanella P; Valcamonico F; Zamparini M; Sirotova Z; Chiappino I; Dal Canton O; Masini C; Sacco C; Amoroso D; Montagnani F; Comandone A; Bellissimo AR; Ciccone G; Baier S; Gennari A; Tucci M; Berruti A
    Eur J Cancer; 2021 Sep; 155():127-135. PubMed ID: 34371442
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Enhancing the effectiveness of androgen deprivation in prostate cancer by inducing Filamin A nuclear localization.
    Mooso BA; Vinall RL; Tepper CG; Savoy RM; Cheung JP; Singh S; Siddiqui S; Wang Y; Bedolla RG; Martinez A; Mudryj M; Kung HJ; Devere White RW; Ghosh PM
    Endocr Relat Cancer; 2012 Dec; 19(6):759-77. PubMed ID: 22993077
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development of 5D3-DM1: A Novel Anti-Prostate-Specific Membrane Antigen Antibody-Drug Conjugate for PSMA-Positive Prostate Cancer Therapy.
    Huang CT; Guo X; Bařinka C; Lupold SE; Pomper MG; Gabrielson K; Raman V; Artemov D; Hapuarachchige S
    Mol Pharm; 2020 Sep; 17(9):3392-3402. PubMed ID: 32803984
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The predictive value of ERG protein expression for development of castration-resistant prostate cancer in hormone-naïve advanced prostate cancer treated with primary androgen deprivation therapy.
    Berg KD; Røder MA; Thomsen FB; Vainer B; Gerds TA; Brasso K; Iversen P
    Prostate; 2015 Oct; 75(14):1499-509. PubMed ID: 26053696
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-effectiveness of enzalutamide versus apalutamide versus androgen deprivation therapy alone for the treatment of metastatic castration-sensitive prostate cancer in Canada.
    Saad F; Chilelli A; Hui B; Muratov S; Ganguli A; North S; Shayegan B
    J Med Econ; 2022; 25(1):583-590. PubMed ID: 35469527
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Risk factors for early castration-resistant prostate cancer after androgen deprivation therapy for bone-metastatic prostate cancer].
    Huang FM; Li XH; Liang Y
    Zhonghua Nan Ke Xue; 2018 Aug; 24(8):690-694. PubMed ID: 30173426
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Platelet-Synthesized Testosterone in Men with Prostate Cancer Induces Androgen Receptor Signaling.
    Zaslavsky AB; Gloeckner-Kalousek A; Adams M; Putluri N; Venghatakrishnan H; Li H; Morgan TM; Feng FY; Tewari M; Sreekumar A; Palapattu GS
    Neoplasia; 2015 Jun; 17(6):490-6. PubMed ID: 26152357
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Concurrent Androgen and Estrogen Ablation and Inhibition of Steroid Biosynthetic Enzyme Treatment for Castration-resistant Prostate Cancer.
    Sinha AA; Pomroy FE; Wilson MJ
    Anticancer Res; 2016 Aug; 36(8):3847-54. PubMed ID: 27466486
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy.
    Barata P; Emamekhoo H; Mendiratta P; Koshkin V; Tyler A; Ornstein M; Rini BI; Gilligan T; Kyriakopoulos C; Garcia JA
    Prostate; 2018 Sep; 78(13):1035-1041. PubMed ID: 29882332
    [TBL] [Abstract][Full Text] [Related]  

  • 53. New TRPM8 blockers exert anticancer activity over castration-resistant prostate cancer models.
    Di Sarno V; Giovannelli P; Medina-Peris A; Ciaglia T; Di Donato M; Musella S; Lauro G; Vestuto V; Smaldone G; Di Matteo F; Bifulco G; Castoria G; Migliaccio A; Fernandez-Carvajal A; Campiglia P; Gomez-Monterrey I; Ostacolo C; Bertamino A
    Eur J Med Chem; 2022 Aug; 238():114435. PubMed ID: 35598411
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Real-world survival outcomes of adding docetaxel or abiraterone in patients with high-volume metastatic castration-sensitive prostate cancer: historically controlled, propensity score matched comparison with androgen deprivation therapy.
    Narita S; Kimura T; Hatakeyama S; Hata K; Yanagisawa T; Maita S; Chiba S; Sato H; Kashima S; Koizumi A; Yamamoto R; Takayama K; Okane K; Ishida T; Horikawa Y; Kumazawa T; Shimoda J; Suzuki T; Ohyama C; Egawa S; Nomura K; Habuchi T
    World J Urol; 2022 May; 40(5):1135-1141. PubMed ID: 35218371
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Systematically understanding the immunity leading to CRPC progression.
    Ji Z; Zhao W; Lin HK; Zhou X
    PLoS Comput Biol; 2019 Sep; 15(9):e1007344. PubMed ID: 31504033
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Androgen deprivation‑induced OPHN1 amplification promotes castration‑resistant prostate cancer.
    Liu J; Zhang Y; Li S; Sun F; Wang G; Wei D; Yang T; Gu S
    Oncol Rep; 2022 Jan; 47(1):. PubMed ID: 34738630
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recent trends in the management of advanced prostate cancer.
    Ritch C; Cookson M
    F1000Res; 2018; 7():. PubMed ID: 30345007
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up.
    Studer UE; Whelan P; Wimpissinger F; Casselman J; de Reijke TM; Knönagel H; Loidl W; Isorna S; Sundaram SK; Collette L;
    Eur Urol; 2014 Nov; 66(5):829-38. PubMed ID: 23932338
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Association of prostate cancer SLCO gene expression with Gleason grade and alterations following androgen deprivation therapy.
    Alsinnawi M; Zhang A; Bianchi-Frias D; Burns J; Cho E; Zhang X; Sowalsky A; Ye H; Slee AE; True L; Porter C; Taplin ME; Balk S; Nelson PS; Montgomery RB; Mostaghel EA
    Prostate Cancer Prostatic Dis; 2019 Dec; 22(4):560-568. PubMed ID: 30890759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.